609 related articles for article (PubMed ID: 34668743)
1. Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.
Miró-Canturri A; Vila-Domínguez A; Caretero-Ledesma M; Ayerbe-Algaba R; Pachón J; Jiménez-Mejías ME; Smani Y
Microbiol Spectr; 2021 Oct; 9(2):e0040321. PubMed ID: 34668743
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis.
Domínguez-Herrera J; Docobo-Pérez F; López-Rojas R; Pichardo C; Ruiz-Valderas R; Lepe JA; Pachón J
Antimicrob Agents Chemother; 2012 Feb; 56(2):613-7. PubMed ID: 22123684
[TBL] [Abstract][Full Text] [Related]
3. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
5. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
[TBL] [Abstract][Full Text] [Related]
6. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP
J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
8. Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic.
Cheung Lam AH; Sandoval N; Wadhwa R; Gilkes J; Do TQ; Ernst W; Chiang SM; Kosina S; Howard Xu H; Fujii G; Porter E
BMC Res Notes; 2016 Jul; 9():337. PubMed ID: 27391402
[TBL] [Abstract][Full Text] [Related]
9. The issue beyond resistance: Methicillin-resistant Staphylococcus epidermidis biofilm formation is induced by subinhibitory concentrations of cloxacillin, cefazolin, and clindamycin.
Mirzaei R; Yousefimashouf R; Arabestani MR; Sedighi I; Alikhani MY
PLoS One; 2022; 17(11):e0277287. PubMed ID: 36350834
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
Ueda Y; Sunagawa M
Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors of early fecal carriage of Enterococcus faecalis and Staphylococcus spp and their antimicrobial resistant patterns among healthy neonates born in a hospital setting in central Saudi Arabia.
El-Kersh TA; Marie MA; Al-Sheikh YA; Al-Agamy MH; Al Bloushy AA
Saudi Med J; 2016 Mar; 37(3):280-7. PubMed ID: 26905350
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
[TBL] [Abstract][Full Text] [Related]
13. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
Li JT; Li Y; Wang J;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
[TBL] [Abstract][Full Text] [Related]
14. Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.
Miró-Canturri A; Ayerbe-Algaba R; Vila-Domínguez A; Jiménez-Mejías ME; Pachón J; Smani Y
Antibiotics (Basel); 2021 Mar; 10(3):. PubMed ID: 33810067
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producing methicillin-resistant Staphylococcus epidermidis.
Domínguez-Herrera J; López-Rojas R; Smani Y; Labrador-Herrera G; Pachón J
Int J Antimicrob Agents; 2016 Dec; 48(6):661-665. PubMed ID: 28128094
[TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of linezolid/ertapenem combination in resistant gram-positive bacteria].
Eraç B; Taşli H; Ermertcan S; Cilli F; Limoncu MH
Mikrobiyol Bul; 2009 Jan; 43(1):45-51. PubMed ID: 19334379
[TBL] [Abstract][Full Text] [Related]
17. In-vitro selection of resistance to vancomycin and teicoplanin in Enterococcus faecium and Enterococcus faecalis compared with Staphylococcus epidermidis.
Markopulos E; Graninger W; Georgopoulos A
J Antimicrob Chemother; 1998 Jan; 41(1):43-7. PubMed ID: 9511036
[TBL] [Abstract][Full Text] [Related]
18. Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium.
Gargvanshi S; Gutheil WG
Microbiol Spectr; 2022 Oct; 10(5):e0141222. PubMed ID: 35969069
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
[TBL] [Abstract][Full Text] [Related]
20. Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays.
D'Arezzo S; Mazzarelli A; Venditti C; Nisii C; Petrosillo N; De Giuli C; Vulcano A; Paglia MG; Bordi E; Di Caro A; Taglietti F
Microb Drug Resist; 2017 Jun; 23(4):507-515. PubMed ID: 27526275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
